Literature DB >> 32744608

Expanded Clinical Phenotype, Oncological Associations, and Immunopathologic Insights of Paraneoplastic Kelch-like Protein-11 Encephalitis.

Divyanshu Dubey1,2,3,4, Michael R Wilson5, Benjamin Clarkson2,4, Caterina Giannini1,4, Manish Gandhi1, John Cheville1, Vanda A Lennon1,2,3,4, Scott Eggers2, Michelle F Devine1,4, Caleigh Mandel-Brehm6, Thomas Kryzer2,4, Shannon R Hinson2,4, Khashayarsha Khazaie3, Chadwick Hales7, Jorge Kattah8, Kevin D Pavelko3, Patrick Andrews2,4, James E Eaton9, Jiraporn Jitprapaikulsan4,10, John R Mills1,4, Eoin P Flanagan1,2,4, Anastasia Zekeridou1,2,4, Bradley Leibovich11, James Fryer2,4, Matthew Torre12, Charles Kaufman13, James B Thoreson1, Jessica Sagen1,2,4, Jenny J Linnoila14, Joseph L DeRisi6,15, Charles L Howe2,3,4, Andrew McKeon1,2,4, Sean J Pittock1,2,4.   

Abstract

Importance: Recognizing the presenting and immunopathological features of Kelch-like protein-11 immunoglobulin G seropositive (KLHL11 IgG+) patients may aid in early diagnosis and management. Objective: To describe expanding neurologic phenotype, cancer associations, outcomes, and immunopathologic features of KLHL11 encephalitis. Design, Setting, and Participants: This retrospective tertiary care center study, conducted from October 15, 1998, to November 1, 2019, prospectively identified 31 KLHL11 IgG+ cases in the neuroimmunology laboratory. Eight were identified by retrospective testing of patients with rhomboencephalitis (confirmed by tissue-based-immunofluorescence and transfected-cell-based assays). Main Outcomes and Measures: Outcome variables included modified Rankin score and gait aid use.
Results: All 39 KLHL11 IgG+ patients were men (median age, 46 years; range, 28-73 years). Initial clinical presentations were ataxia (n = 32; 82%), diplopia (n = 22; 56%), vertigo (n = 21; 54%), hearing loss (n = 15; 39%), tinnitus (n = 14; 36%), dysarthria (n = 11; 28%), and seizures (n = 9; 23%). Atypical neurologic presentations included neuropsychiatric dysfunction, myeloneuropathy, and cervical amyotrophy. Hearing loss or tinnitus preceded other neurologic deficits by 1 to 8 months in 10 patients (26%). Among patients screened for malignancy (n = 36), testicular germ-cell tumors (n = 23; 64%) or testicular microlithiasis and fibrosis concerning for regressed germ cell tumor (n = 7; 19%) were found in 83% of the patients (n = 30). In 2 patients, lymph node biopsy diagnosed metastatic lung adenocarcinoma in one and chronic lymphocytic leukemia in the other. Initial brain magnetic resonance imaging revealed T2 hyperintensities in the temporal lobe (n = 12), cerebellum (n = 9), brainstem (n = 3), or diencephalon (n = 3). Among KLHL11 IgG+ patients who underwent HLA class I and class II genotyping (n = 10), most were found to have HLA-DQB1*02:01 (n = 7; 70%) and HLA-DRB1*03:01 (n = 6; 60%) associations. A biopsied gadolinium-enhancing temporal lobe lesion demonstrated T cell-predominant inflammation and nonnecrotizing granulomas. Cerebellar biopsy (patient with chronic ataxia) and 2 autopsied brains demonstrated Purkinje neuronal loss and Bergmann gliosis, supporting early active inflammation and later extensive neuronal loss. Compared with nonautoimmune control peripheral blood mononuclear cells, cluster of differentiation (CD) 8+ and CD4+ T cells were significantly activated when patient peripheral blood mononuclear cells were cultured with KLHL11 protein. Most patients (58%) benefitted from immunotherapy and/or cancer treatment (neurological disability stabilized [n = 10] or improved [n = 9]). Kaplan-Meier curve demonstrated significantly higher probability of wheelchair dependence among patients without detectable testicular cancer. Long-term outcomes in KLHL11-IgG+ patients were similar to Ma2 encephalitis. Conclusions and Relevance: Kelch-like protein-11 IgG is a biomarker of testicular germ-cell tumor and paraneoplastic neurologic syndrome, often refractory to treatment. Described expanded neurologic phenotype and paraclinical findings may aid in its early diagnosis and treatment.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32744608      PMCID: PMC7653501          DOI: 10.1001/jamaneurol.2020.2231

Source DB:  PubMed          Journal:  JAMA Neurol        ISSN: 2168-6149            Impact factor:   18.302


  24 in total

Review 1.  Paraneoplastic neurological syndrome: growing spectrum and relevance.

Authors:  Valakunja Harikrishna Ganaraja; Mohamed Rezk; Divyanshu Dubey
Journal:  Neurol Sci       Date:  2022-04-23       Impact factor: 3.307

2.  Homer-3 Antibody Disease: A Potentially Treatable MSA-C Mimic.

Authors:  Eoin Mulroy; Bettina Balint; Kailash P Bhatia
Journal:  Mov Disord Clin Pract       Date:  2022-01-08

3.  Commentary: Paraneoplastic Syndrome Associated with Kelch-Like Protein 11 Antibodies Presenting with Progressive Ataxia and Tremor.

Authors:  Alfonso Fasano; Prarthana Prakash; Ian O Bledsoe; Bettina Balint
Journal:  Mov Disord Clin Pract       Date:  2021-09-03

4.  Paraneoplastic Syndrome Associated with Kelch-Like Protein 11 Antibodies Presenting with Progressive Ataxia and Tremor.

Authors:  Prarthana Prakash; Ian O Bledsoe
Journal:  Mov Disord Clin Pract       Date:  2021-09-03

Review 5.  Sleep Disturbances Associated with Neurological Autoimmunity.

Authors:  Michelle F Devine; Erik K St Louis
Journal:  Neurotherapeutics       Date:  2021-03-30       Impact factor: 7.620

6.  Distinctive clinical presentation and pathogenic specificities of anti-AK5 encephalitis.

Authors:  Sergio Muñiz-Castrillo; Julien Jacques Hedou; Aditya Ambati; David Jones; Alberto Vogrig; Anne-Laurie Pinto; Marie Benaiteau; Thomas de Broucker; Laura Fechtenbaum; Pierre Labauge; Matthew Murnane; Claire Nocon; Irina Taifas; Clément Vialatte de Pémille; Dimitri Psimaras; Bastien Joubert; Valérie Dubois; Valentin Wucher; Virginie Desestret; Emmanuel Mignot; Jérôme Honnorat
Journal:  Brain       Date:  2021-10-22       Impact factor: 13.501

7.  Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes.

Authors:  Francesc Graus; Alberto Vogrig; Sergio Muñiz-Castrillo; Jean-Christophe G Antoine; Virginie Desestret; Divyanshu Dubey; Bruno Giometto; Sarosh R Irani; Bastien Joubert; Frank Leypoldt; Andrew McKeon; Harald Prüss; Dimitri Psimaras; Laure Thomas; Maarten J Titulaer; Christian A Vedeler; Jan J Verschuuren; Josep Dalmau; Jerome Honnorat
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2021-05-18

Review 8.  Antibody-Mediated Autoimmune Diseases of the CNS: Challenges and Approaches to Diagnosis and Management.

Authors:  Elia Sechi; Eoin P Flanagan
Journal:  Front Neurol       Date:  2021-07-07       Impact factor: 4.003

9.  Paraneoplastic disorders of the nervous system.

Authors:  Eoin P Flanagan
Journal:  J Neurol       Date:  2021-04-27       Impact factor: 6.682

Review 10.  Paraneoplastic neurological syndrome: an evolving story.

Authors:  Jiraporn Jitprapaikulsan; Pritikanta Paul; Smathorn Thakolwiboon; Shivam Om Mittal; Sean J Pittock; Divyanshu Dubey
Journal:  Neurooncol Pract       Date:  2021-02-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.